Overview

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Procter and Gamble